search
Back to results

European Novel Motorized Spiral Endoscopy Trial (ENMSET)

Primary Purpose

Disorder of Small Intestine, Gastrointestinal Hemorrhage, Iron Deficiency Anaemia

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
motorized spiral enteroscopy
Sponsored by
Evangelisches Krankenhaus Düsseldorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Disorder of Small Intestine focused on measuring endoscopy, small bowel endoscopy, motorized spiral endoscopy, spiral endoscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Overt obscure gastrointestinal bleeding or obscure gastrointestinal bleeding or indeterminate iron-deficiency anaemia and positive videocapsule endoscopy (VCE) or negative VCE in patients who have ongoing bleeding shown by overt bleeding or continued need for blood transfusions
  • Abdominal pain or chronic diarrhoea with positive findings of small bowel imaging examinations
  • Noncontributory ileocolonoscopy and suspicion of Crohn's disease on small-bowel cross-sectional imaging modalities or small-bowel capsule endoscopy
  • Further evaluation of known Crohn's disease or therapeutic indications in Crohn's disease
  • Imaging tests suspicious for small-bowel tumour
  • Large polyps (>10-15mm) discovered by radiological examination or small-bowel capsule endoscopy in patients with Peutz-Jeghers syndrome
  • Nonresponsive or refractory coeliac disease

Exclusion Criteria:

  • Age under 18 years
  • Health status American Society of Anesthesiologists classification (ASA) 4
  • Pregnancy
  • Coagulopathy (INR≥2.0, Platelets < 70/nl)
  • Taking anti-platelet agents or anticoagulants (other than aspirin) within last 7 days
  • Any medical contraindication to standard enteroscopy
  • Presence of any intraluminal or extraluminal foreign body in the abdominal cavity
  • Any prior gastric, small bowel or colonic surgery, or implantable devices in these locations (cardiac pacemakers and non-abdominal implants are acceptable)
  • Known or suspected bowel obstruction or stenosis or history of bowel obstruction
  • Known coagulation disorder
  • Known or suspected esophageal stricture or Schatzki ring
  • Known gastric or esophageal varices
  • Suspected perforation of the GI tract
  • Inability to tolerate sedation or general anesthesia for any reason
  • Inability to tolerate endotracheal intubation
  • Absence of a signed informed consent

Sites / Locations

  • Universite Libre des Bruxelles
  • Evangelisches Krankenhaus

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

motorized spiral enteroscopy

Arm Description

Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.

Outcomes

Primary Outcome Measures

Diagnostic yield of NMSE in patients with suspected small bowel diseases

Secondary Outcome Measures

Procedural success
Procedural time (minutes)
Depth of maximal insertion (cm)
Therapeutic yield
Adverse events

Full Information

First Posted
November 11, 2016
Last Updated
February 13, 2018
Sponsor
Evangelisches Krankenhaus Düsseldorf
Collaborators
Olympus
search

1. Study Identification

Unique Protocol Identification Number
NCT02965209
Brief Title
European Novel Motorized Spiral Endoscopy Trial
Acronym
ENMSET
Official Title
European Novel Motorized Spiral Endoscopy Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
February 3, 2018 (Actual)
Study Completion Date
February 6, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Evangelisches Krankenhaus Düsseldorf
Collaborators
Olympus

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The subject Novel Motorized Spiral Enteroscope (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. The system is similar to other currently marketed endoscopes in that it incorporates a flexible insertion tube, light source, digital imaging, and channels for passing accessories for sample collection or therapeutic interventions. The NMSE system is unique in that it incorporates a user-controlled motor contained in the endoscope's handle to rotate a spiral cuff located on the endoscope's insertion tube. Rotation of this cuff, which has soft spiral-shaped "fins", pleats the small bowel on to the endoscope's insertion tube, thereby allowing rapid and atraumatic access deep into the small bowel. The system also includes a display monitor, a motor control unit, device to display measured motor current and signal torque, and a set of foot pedals. Motorization of the Spiral Enteroscope and limitation of rotation to a short cuff instead of a long overtube promise to accelerate the procedure, to facilitate insertion and to improve maneuvering the instrument in comparison to conventional spiral enteroscopy
Detailed Description
General anesthesia and/or sedation will be prescribed according to institutional practices and clinical judgment; type, amount and duration will be recorded. A standard esophagogastroduodenoscopy (EGD) will be performed prior to the enteroscopy. If during this preliminary exam the endoscopist identifies any stricture or believes the patient has anatomy that would cause excessive resistance during Novel Motorized Spiral insertion or examination, the patient will be withdrawn from the study and the reason for study withdrawal will be noted. The Novel Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, (controlled directly by the operating physician via the foot pedal). If at any point a stricture is observed or excessive resistance to the advancement of the endoscope is encountered, further advancement of the endoscope must cease and the reason for procedure termination documented on the case report form. After reaching the depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. Maximum depth of insertion will be recorded as the maximum insertion depth when failure to advance the endoscope tip after repositioning the patient, applying abdominal pressure and/or using other standard measures fails to advance the endoscope OR the investigator decides to terminate advancement based on clinical judgment. During withdrawal, the endoscopist will cumulatively estimate the length of bowel released from the endoscope tip in order to calculate the total depth of insertion. Insertion depth will be referenced to the Ligament Treitz. If the clinician decides to mark the point of maximum insertion, the tissue may be tattooed by first creating a saline bleb, followed by the injection of India ink (e.g., SPOT). Tissue sampling and/or therapies will be performed during withdrawal as clinically appropriate. The details of all sampling and/or therapies (number, type & location) will be recorded. The comfort and cardiopulmonary stability of the patient will be monitored throughout the procedure, as per the standard of care - this includes continuous pulse oximetry, blood pressure, and heart rate monitoring. Photographs or video recordings are used to document any significant lesions and any tissue trauma. Postprocedural measures Patients will be hospitalized for at least 24 hours after NMSE because of the potential risk of delayed adverse events. Only liquid diet is allowed during the first 12 hours in asymptomatic patients. Clinical investigation and determination of the blood cell count and the serum level of C-reactive protein will be done after 24 hours. 30 days after the procedure patients will be interviewed by a telephone call for evaluation of complaints or delayed complications. Discomfort (location and severity (0-10 VAS) should be documented immediately after NMSE, after 24 hours and before discharge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Disorder of Small Intestine, Gastrointestinal Hemorrhage, Iron Deficiency Anaemia, Crohn's Disease, Small Bowel Tumors, Intestinal Polyposis Syndrome, Coeliac Disease
Keywords
endoscopy, small bowel endoscopy, motorized spiral endoscopy, spiral endoscopy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
136 (Actual)

8. Arms, Groups, and Interventions

Arm Title
motorized spiral enteroscopy
Arm Type
Experimental
Arm Description
Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
Intervention Type
Procedure
Intervention Name(s)
motorized spiral enteroscopy
Other Intervention Name(s)
standard endoscopic interventions (not experimental)
Intervention Description
Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
Primary Outcome Measure Information:
Title
Diagnostic yield of NMSE in patients with suspected small bowel diseases
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Procedural success
Time Frame
30 days
Title
Procedural time (minutes)
Time Frame
30 days
Title
Depth of maximal insertion (cm)
Time Frame
30 days
Title
Therapeutic yield
Time Frame
30 days
Title
Adverse events
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Overt obscure gastrointestinal bleeding or obscure gastrointestinal bleeding or indeterminate iron-deficiency anaemia and positive videocapsule endoscopy (VCE) or negative VCE in patients who have ongoing bleeding shown by overt bleeding or continued need for blood transfusions Abdominal pain or chronic diarrhoea with positive findings of small bowel imaging examinations Noncontributory ileocolonoscopy and suspicion of Crohn's disease on small-bowel cross-sectional imaging modalities or small-bowel capsule endoscopy Further evaluation of known Crohn's disease or therapeutic indications in Crohn's disease Imaging tests suspicious for small-bowel tumour Large polyps (>10-15mm) discovered by radiological examination or small-bowel capsule endoscopy in patients with Peutz-Jeghers syndrome Nonresponsive or refractory coeliac disease Exclusion Criteria: Age under 18 years Health status American Society of Anesthesiologists classification (ASA) 4 Pregnancy Coagulopathy (INR≥2.0, Platelets < 70/nl) Taking anti-platelet agents or anticoagulants (other than aspirin) within last 7 days Any medical contraindication to standard enteroscopy Presence of any intraluminal or extraluminal foreign body in the abdominal cavity Any prior gastric, small bowel or colonic surgery, or implantable devices in these locations (cardiac pacemakers and non-abdominal implants are acceptable) Known or suspected bowel obstruction or stenosis or history of bowel obstruction Known coagulation disorder Known or suspected esophageal stricture or Schatzki ring Known gastric or esophageal varices Suspected perforation of the GI tract Inability to tolerate sedation or general anesthesia for any reason Inability to tolerate endotracheal intubation Absence of a signed informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Horst Neuhaus, MD
Organizational Affiliation
Evangelisches Krankenhaus Duesseldorf
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universite Libre des Bruxelles
City
Brussels
Country
Belgium
Facility Name
Evangelisches Krankenhaus
City
Duesseldorf
ZIP/Postal Code
40217
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32332141
Citation
Beyna T, Arvanitakis M, Schneider M, Gerges C, Boing D, Deviere J, Neuhaus H. Motorised spiral enteroscopy: first prospective clinical feasibility study. Gut. 2021 Feb;70(2):261-267. doi: 10.1136/gutjnl-2019-319908. Epub 2020 Apr 24.
Results Reference
derived

Learn more about this trial

European Novel Motorized Spiral Endoscopy Trial

We'll reach out to this number within 24 hrs